Exciting New Leadership Appointments at Dyne Therapeutics
Waltham, Massachusetts – April 15, 2025
Dyne Therapeutics, a pioneering clinical-stage company dedicated to transforming lives for those living with genetically driven neuromuscular diseases, is thrilled to announce the appointments of two esteemed scientists, Vikram Ranade, PhD, and Ranjan Batra, PhD, to the key executive positions of Chief Business Officer (CBO) and Chief Scientific Officer (CSO), respectively.
Vikram Ranade, PhD: A Proven Business Leader
Dr. Ranade brings extensive experience in business development, strategy, and operations to Dyne. He previously held senior leadership roles at several notable biotech companies, where he was instrumental in driving growth and strategic partnerships.
Ranjan Batra, PhD: A Renowned Scientific Mind
Dr. Batra is a renowned scientist with a distinguished career in research and development. He comes to Dyne from a prestigious research institution, where he led groundbreaking studies in neuromuscular diseases. Dr. Batra’s appointment as CSO will further strengthen Dyne’s commitment to scientific innovation and excellence.
Oxana Beskrovnaya, PhD: Transitioning to Chief Innovation Officer
Dr. Beskrovnaya, who has served as Dyne’s Vice President of Research, will transition to the role of Chief Innovation Officer. In this new position, she will focus on driving the company’s innovation strategy and collaborations, ensuring Dyne remains at the forefront of the neuromuscular therapeutics field.
Impact on You: Hope for the Future of Neuromuscular Diseases
- These appointments signal a renewed commitment to advancing transformative treatments for people living with neuromuscular diseases.
- With the combined expertise of Dr. Ranade, Dr. Batra, and Dr. Beskrovnaya, Dyne is poised to make significant strides in research and development.
- As a patient or a caregiver, you can look forward to new treatment options and hope for the future.
Impact on the World: A Brighter Future for Neuromuscular Diseases
- These appointments represent a significant investment in the field of neuromuscular diseases, which affects millions of people worldwide.
- Dyne’s continued innovation and advancements in treatments could lead to improved quality of life and even cures for those affected by these conditions.
- The global community can look forward to a future where neuromuscular diseases are no longer a debilitating and life-altering diagnosis.
About Dyne Therapeutics: Dyne Therapeutics, Inc. is a clinical-stage company dedicated to transforming lives for those living with genetically driven neuromuscular diseases. Dyne’s mission is to develop and deliver innovative therapies that address the underlying causes of these debilitating conditions. For more information, please visit www.dyne-therapeutics.com.
Conclusion: A New Chapter in Dyne’s Journey
With the appointments of Dr. Ranade and Dr. Batra, and the transition of Dr. Beskrovnaya, Dyne Therapeutics is entering a new and exciting chapter in its journey to transform lives for those living with neuromuscular diseases. We are confident that their combined expertise and dedication will lead to groundbreaking innovations and new treatment options.
As a patient, caregiver, or member of the global community, we invite you to join us on this journey as we work towards a brighter future for those affected by neuromuscular diseases.
